Replies to post #8574 on Biotech Values

[urche]

PAP vs PSMA


<<5) This abstract reminds me of what has always made me nervous about Provenge---the fact that the vaccine is based on PAP, not a very specific and far from ideal prostate cancer antigen.>>

Walldiver asked the multi million dollar question:

"Are you sure about that?"

I wish I had more clarity. I don't have time right now to cite some older references, but from research about 18 months ago, I was impressed that PSMA was probably a better prostate cancer target. Thus, I have always had q queasy feeling that Provenge may be a lot of research money spent on a good, but not the ultimate product. (But, Progenics and its PSMA collaboration have their own problems)
Perhaps I can dig out some background tonight.

Urche